Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection or Inflammation Clear all

Conditions: Methicillin Resistant Staphylococcus Aureus Skin Infections
Interventions: mupirocin and chlorhexidine, household cleaning and disinfection, mupirocin, chlorhexidine, & household cleaning/disinfection; Drug · Behavioral
Lead sponsor: loren g miller; Other
Eligibility: 1 Month and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Anaheim, California • Bellflower, California • Harbor City, California + 3 more

Conditions: Catheter Infections, Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Interventions: Chlorhexidine impregnated patch (Biopatch); Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Malaria
Interventions: PfSPZ Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Candidiasis, Invasive, Candidemia
Interventions: SCY-078, Fluconazole, Echinocandin; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more

Conditions: Lung Transplant; Complications, Lung Transplant; Infection or Inflammation, Lung Transplant Rejection, Lung Transplant Failure
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 14 more

Conditions: Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions: OMNIPHYS Multimodal Ultrasound Imaging System; Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2046
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection, Acute Kidney Injury, Sepsis
Interventions: Piperacillin + Tazobactam, meropenem; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Cooperstown, New York + 4 more

Conditions: Inflammation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Maternal; Chorioamnionitis, Affecting Fetus, Early-Onset Sepses, Neonatal
Interventions: EOS Calculator; Diagnostic Test
Lead sponsor: Pediatrix; Other
Eligibility: 35 Weeks and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Albany, New York

Conditions: Cytokine Release Syndrome, COVID19
Interventions: Therapeutic Plasma Exchange, Ruxolitinib; Procedure · Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 12 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cellulitis
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Suture, Complication, Wound, Wound Complication, Wound Dehiscence, Wound of Skin, Surgery, Suture; Complications, Infection or Inflammation
Interventions: Suture spacing for wound closure; Other
Lead sponsor: Silver Falls Dermatology; Other
Eligibility: 30 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salem, Oregon

Conditions: Breast Implant; Complications, Infection or Inflammation
Interventions: Not listed
Lead sponsor: AlloSource; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation
Interventions: Chlorhexidine, Gentamicin, Rifampin; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Mountain View, California • Chicago, Illinois • Des Plaines, Illinois

Conditions: Candidiasis, Candidemia
Interventions: Micafungin, Caspofungin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 62
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more

Conditions: Bacteremia
Interventions: dalbavancin; Drug
Lead sponsor: Vicuron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Abdominal Abscess, Tissue Plasminogen Activator
Interventions: Tissue plasminogen activator abscess flush, Saline flush of abscess; Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 17 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Sepsis, Hypotension, Septic Shock
Interventions: NICOM; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hidradenitis Suppurativa
Interventions: Olatorepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Endocarditis, Bacteremia
Interventions: Dalbavancin, Standard of Care; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Ft. Pierce, Florida

Conditions: Severe Sepsis
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Septic Shock
Interventions: Early Vasopressors, Early Fluids; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 50
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 36 more

Search by objective public record fields.

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes

Multimodal Physiologic State Intelligence Study

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders

A Chart Review of Newborns With the Presence of Confirmed or Suspected Maternal Chorioamnionitis and Utilization of the Early Onset Sepsis Calculator

Biomarker Analysis of Stress

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Screening for NEI Clinical Studies

Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas

Split Scar Study to Assess Cosmetic Outcome From Differing Suture Spacing

Histological Analysis of AlloMend® Acellular Dermal Matrix Used in Breast Implant Surgeries

Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

Treatment of Abdominal Abscesses With or Without Fibrinolysis

Non-Invasive Cardiac Output Monitor (NICOM) for Goal-directed Fluid Resuscitation for Inpatients With Hypotension and/or Septic Shock

Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

Symphony IL-6 Study in Patients at Risk of Severe Sepsis

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis